aica ribonucleotide has been researched along with Allergic Encephalomyelitis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, S; Samuvel, DJ; Saxena, N; Singh, AK; Singh, I; Won, J | 1 |
| Giri, S; Nath, N; Prasad, R; Salem, ML; Singh, AK; Singh, I | 1 |
| Giri, S; Nath, N; Prasad, R; Singh, AK; Singh, I | 1 |
| Paintlia, AS; Paintlia, MK; Singh, AK; Singh, I | 1 |
4 other study(ies) available for aica ribonucleotide and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model.
Topics: Adenosine Triphosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Biomarkers; Cell Line; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression; Humans; Lovastatin; Mice; Mitochondria; Peroxisomes; rho-Associated Kinases; rhoA GTP-Binding Protein; Ribonucleotides; Spinal Cord | 2018 |
5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antigen Presentation; Cytokines; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimental; Enzyme Activation; Female; GATA3 Transcription Factor; Glycoproteins; Humans; Immunologic Factors; Interleukin-10; Mice; Mice, Inbred C57BL; Multienzyme Complexes; Multiple Sclerosis; Myelin Proteolipid Protein; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Protein Serine-Threonine Kinases; Ribonucleotides; T-Box Domain Proteins; Th1 Cells; Th2 Cells; Trans-Activators; Transcription Factors | 2005 |
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside attenuates experimental autoimmune encephalomyelitis via modulation of endothelial-monocyte interaction.
Topics: Aminoimidazole Carboxamide; Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Cell Adhesion; Cell Adhesion Molecules; Chemotaxis, Leukocyte; Disease Models, Animal; Down-Regulation; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Female; Inflammation Mediators; Mice; Monocytes; NF-kappa B; Rats; Rats, Inbred Lew; Ribonucleotides; Tumor Necrosis Factor-alpha | 2006 |
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme Activation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Immunoglobulin G; Immunologic Factors; Lovastatin; Multienzyme Complexes; Multiple Sclerosis; Myelin Basic Protein; Protein Serine-Threonine Kinases; Rats; Rats, Inbred Lew; Ribonucleotides; Th1 Cells; Th2 Cells | 2006 |